ReACp53

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

ReACp53  纯度: 99.39%

ReACp53 能够抑制 p53 amyloid 的形成, 挽救 p53 在癌细胞中的作用。

ReACp53

ReACp53 Chemical Structure

规格 价格 是否有货 数量
1 mg ¥1000 In-stock
5 mg ¥3000 In-stock
10 mg ¥4500 In-stock
25 mg ¥8000 In-stock
50 mg ¥13000 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

ReACp53 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Peptide Library

生物活性

ReACp53 could inhibit p53 amyloid formation and rescue p53 function in cancer cell lines.

IC50 & Target

p53 amyloid formation[1].

体外研究
(In Vitro)

ReACp53 penetrates into HGSOC primary cancer cells and converts mutant p53 from a punctate state into soluble WT-like p53. ReACp53 also induces cancer cell death, cell cycle arrest and results in p53 degradation. ReACp53 specifically affects cell viability and proliferation of cancer cells bearing mutant p53 but not wild type when grown as organoids[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Only mutant p53-bearing tumors in the ReACp53-treated mice cohorts are 80-90% smaller in weight than the control cohort, confirming the ability of ReACp53 to limit tumor proliferation and shrink tumors. A significant reduction of Ki67 positive cells is evident in ReACp53-treated OVCAR3 xenografts, indicative of a reduced proliferative index. Similar results are observed in the minimal residual disease model. In the paradigm, administration of ReACp53 results in a significant increase in p21 and MDM2 transcription in OVCAR3 but not MCF7 xenografts. A significantly increased population is also found in G0/G1 phase, supporting proliferative arrest upon ReACp53 administration in vivo[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

2617.13

Formula

C108H206N52O24

Sequence Shortening

HRRRRRRRRRRPILTRITLE-OH

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -80°C 2 years
-20°C 1 year
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (38.21 mM; Need ultrasonic)

H2O : 25 mg/mL (9.55 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.3821 mL 1.9105 mL 3.8210 mL
5 mM 0.0764 mL 0.3821 mL 0.7642 mL
10 mM 0.0382 mL 0.1910 mL 0.3821 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (0.96 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (0.96 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (0.96 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (0.96 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (0.96 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (0.96 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Soragni A et al. A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas. Cancer Cell. 2016 Jan 11;29(1):90-103.

Animal Administration
[1]

Mice[1]
In the minimal residual disease model, three cohorts of mice (n=3) are injected with a matrigel/OVCAR3 (p53 mutant) suspension on one flank and with a matrigel/MCF7 (WT p53) suspension on the other flank. Treatment is started the same day. In both models, the treatment phase consist of three weeks of daily IP injections with 15 mg/kg of ReACp53, sequence-scrambled control peptide or vehicle alone[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Soragni A et al. A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas. Cancer Cell. 2016 Jan 11;29(1):90-103.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务